摘要
目的探究泊马度胺(POM)对慢性阻塞性肺疾病(COPD)大鼠的气道炎症和黏液高分泌的作用及其机制。方法将SD大鼠36只随机分为对照组、模型组和POM组,每组12只,雌雄各半。模型组和POM组大鼠采用烟雾暴露联合肺炎克雷伯杆菌感染建立COPD模型,POM组大鼠采用POM(0.5 mg/kg,1次/d,持续1周)干预。观察并检测各组大鼠肺功能、肺组织病理、支气管肺泡灌洗液(BALF)中炎性细胞比例和血清中的炎性因子肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-1β、IL-6、IL-13水平。分别用AB-PAS染色和免疫组织化学法分析大鼠气道上皮杯状细胞增生和黏蛋白(MUC)5AC、MUC5B的分泌情况。Western blotting检测肺组织TNF-α受体1(TNFR1)、IκB激酶(IKK)、磷酸化IKK(p-IKK)和P65蛋白的表达水平。结果与对照组比较,模型组大鼠的潮气量(TV)、每分钟通气量(MV)、用力呼气肺活量(FVC)、0.1 s用力呼气容积(FEV0.1)、0.3 s用力呼气容积(FEV0.3)均降低(P<0.05);肺泡平均线性截距(MLI)升高(P<0.01),平均肺泡数(MAN)降低(P<0.01);BALF沉渣内中性粒细胞、淋巴细胞比例升高(P<0.05),巨噬细胞比例降低(P<0.01);血清炎性因子TNF-α、IL-1β、IL-13和IL-6水平升高(P<0.05);气道上皮杯状细胞比例增高(P<0.01);肺组织MUC5AC和MUC5B分泌增多(P<0.01),TNFR1含量、p-IKK/IKK比值增高(P<0.01),胞核中P65含量增高(P<0.01),胞质中P65含量降低(P<0.05)。与模型组比较,POM治疗一周后,POM组大鼠的TV、MV、FVC、FEV0.1、FEV0.3、MLI、MAN均明显改善(P<0.05);BALF沉渣内中性粒细胞、淋巴细胞比例降低(P<0.05),巨噬细胞比例升高(P<0.01);血清TNF-α、IL-1β、IL-6、IL-13水平降低(P<0.05);气道杯状细胞比例降低(P<0.01),MUC5AC、MUC5B分泌减少(P<0.01),TNFR1、P-IKK、P65(胞核)表达水平降低(P<0.05),P65(胞质)表达水平升高(P<0.01)。结论POM可改善COPD大鼠的气道炎症和黏液高分泌,这种改善作用可能是通过抑制TNF-α/NF-κB信号通路来实现。
Objective To investigate the effect and mechanism of pomalidomide(POM)on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease(COPD).Methods Thirty-six SD rats were randomly divided into control group,model group and POM group,with 12 in each group,half male and half female.The COPD model was established by smoke exposure combined with Klebsiella pneumoniae infection in model group and POM group.The rats in POM group were treated with POM(0.5 mg/kg,once a day for 1 week).The lung function,lung tissue pathology,the proportion of inflammatory cells in bronchoalveolar lavage fluid(BALF)and the levels of serum inflammatory factors tumor necrosis factor-α(TNF‐α),interleukin(IL)‐1β,IL-6 and IL‐13 were observed and detected in each group.AB-PAS staining and immunohistochemistry were used to analyze the proliferation of goblet cells and the secretion of mucin(MUC)5AC and MUC5B in airway epithelium of rats.The expression levels of TNF‐αreceptor 1(TNFR1),IκB kinase(IKK),phosphorylated IKK(p-IKK)and P65 protein in lung tissue were detected by Western blotting.Results Compared with control group,model group showed significant decreased of tidal volume(TV),minute ventilation(MV),forced expiratory vital capacity(FVC),0.1s forced expiratory volume(FEV0.1)and 0.3 s forced expiratory volume(FEV0.3)(P<0.05),increased of the mean linear intercept(MLI)of the alveoli(P<0.01),decreased of the mean alveolar number(MAN)(P<0.01),increased of the proportion of neutrophils and lymphocytes in BALF sediment(P<0.05),and decreased of the proportion of macrophages in BALF sediment(P<0.01);increased of the levels of serum inflammatory factors TNF-α,IL-1β,IL-13 and IL-6(P<0.05),the proportion of goblet cells in airway epithelium(P<0.01),the secretion of MUC5AC and MUC5B in lung tissue(P<0.01),the content of TNFR1 and the ratio of p-IKK/IKK(P<0.01),the content of P65 in nucleus(P<0.01);and decreased of the content of P65 in cytoplasm(P<0.05).Compared with model group,after one week of POM treatment,POM group showed significant improved of the TV,MV,FVC,FEV0.1,FEV0.3,MLI and MAN of rats(P<0.05);decreased of the proportion of neutrophils and lymphocytes in BALF(P<0.05);increased of the proportion of macrophages(P<0.01);decreased of the levels of serum TNF-α,IL-1β,IL-6 and IL-13(P<0.05),the proportion of goblet cells in airway(P<0.01),the secretion of MUC5AC and MUC5B(P<0.01),and the expression of TNFR1,P-IKK and P65(nucleus)(P<0.05);and increased of the level of P65(cytoplasm)(P<0.01).Conclusions POM can improve airway inflammation and mucus hypersecretion in COPD rats,which may be achieved by inhibiting TNF-α/NF-κB signaling pathway.
作者
刘淑娟
李亚
范正媛
李高峰
李素云
Liu Shu-Juan;Li Ya;Fan Zheng-Yuan;Li Gao-Feng;Li Su-Yun(Henan Key Laboratory of Chinese Medicine for Respiratory Disease,Henan University of Chinese Medicine,Zhengzhou,Henan 450046,China;Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of China,Henan University of Chinese Medicine,Zhengzhou,Henan 450046,China;Chinese Medicine Pharmacology(Respiratory)Laboratory,Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou,Henan 450000,China)
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2024年第1期91-98,共8页
Medical Journal of Chinese People's Liberation Army
基金
国家自然科学基金(82074413,81874433)
国家重点研发项目(2018YFC1704801)
中医药传承与创新“百千万”人才工程(岐黄工程)项目岐黄学者([2018]284号)
中原千人计划—中原学者(202101510002)。
